277 related articles for article (PubMed ID: 24896845)
1. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
Gomes-Giacoia E; Miyake M; Goodison S; Sriharan A; Zhang G; You L; Egan JO; Rhode PR; Parker AS; Chai KX; Wong HC; Rosser CJ
PLoS One; 2014; 9(6):e96705. PubMed ID: 24896845
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
Furuya H; Chan OTM; Pagano I; Zhu C; Kim N; Peres R; Hokutan K; Alter S; Rhode P; Rosser CJ
J Transl Med; 2019 Jan; 17(1):29. PubMed ID: 30654801
[TBL] [Abstract][Full Text] [Related]
3. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
4. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
6. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
[TBL] [Abstract][Full Text] [Related]
7. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Anti-Tumor Activity Can Be Achieved by
Esteso G; Aguiló N; Julián E; Ashiru O; Ho MM; Martín C; Valés-Gómez M
Front Immunol; 2021; 12():622995. PubMed ID: 33708215
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).
Saban MR; Simpson C; Davis C; Wallis G; Knowlton N; Frank MB; Centola M; Gallucci RM; Saban R
BMC Immunol; 2007 May; 8():6. PubMed ID: 17506885
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
13. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
14. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
15. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder?
Peters KM; Diokno AC; Steinert BW
Urology; 1999 Sep; 54(3):450-3. PubMed ID: 10475352
[TBL] [Abstract][Full Text] [Related]
19. ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential.
Chen W; Liu N; Yuan Y; Zhu M; Hu X; Hu W; Wang S; Wang C; Huang B; Xing D
Front Immunol; 2022; 13():1040669. PubMed ID: 36439125
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
